KN
Kintor Pharmaceutical Limited
KNTPF · OTC
$0.24 +0.00% (+$0.00)
1M +9.09%
Market Cap ¥754.1M
P/E Ratio -
Div. Yield -
ROE 97.23%
Bulios Fair Price
$0.25
4.2% upside
Current Price
$0.24
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KNTPF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
24 /100
Expensive P/B 4.13x
P/S 23.68x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 50.38%
FCF growth N/A
EPS growth N/A
Profitability
0 /100
Weak Op. margin 619.86%
Gross margin 77.03%
FCF margin 535.45%
Quality
1 /100
Poor ROA 57.17%
ROIC 65.09%
Asset turnover 0.09x
Debt
40 /100
Moderate Int. coverage -51.36x
Debt/Equity 0.47x
Current ratio 0.43x
Stability
32 /100
Unstable Profitable years 0
Beta -0.57x
EPS volatility 55.33%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KNTPF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Youzhi Tong
Employees
123
Headquarters
Suzhou
Upcoming events
01 APR
Earnings
Upcoming earnings report